Business
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
Interim analyses on track for the first and second half of 2026SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced a progress update for the Phase 2 B-SUPREME study of pevifoscorvir sodium in subjects with chronic hepatitis B virus (HBV) infection. “2026 is an important year for Aligos a
About this update from Aligos Therapeutics, Inc.
[{"type":"image","alt":"Aligos Therapeutics","displaySize":"","headline":null,"caption":"Aligos Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/209c9435fdfab4fa4ff642c123fac955"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L8133ghONMF7WN.yZV6tsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/209c9435fdfab4fa4ff642c123fac955","width":150,"height":50}},"lazy":false},{"type":"text","content":"Interim analyses on track for the first and second half of 2026","length":63,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced a progress update for the Phase 2 B-SUPREME study of pevifoscorvir sodium in subjects with chronic hepatitis B virus (HBV) infection.","length":397,"tagName":"p"},{"type":"text","content":"“2026 is an important year for Aligos as we continue to make progress with the Phase 2 B-SUPREME study with 144 subjects currently enrolled across the world,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and CEO. “We look forward to our interim analyses, which will contain directional insights on how the study is tracking. The study remains on track to complete enrollment, with topline data expected in 2027. We believe pevifoscorvir sodium is poised for success in this study and look forward to sharing more details later this year.”","length":552,"tagName":"p"},{"type":"text","content":"Planned Interim Analyses","length":24,"tagName":"p"},{"type":"text","content":"The first protocol defined interim analysis includes approximately 60% (or 36) HBeAg- participants that complete 12 weeks of the treatment period. This enrollment milestone occurred in Q4 2025. In addition, the planned enrollment of this cohort of 60 HBeAg- participants completed in January 2026. The first interim analysis is expected to occur in the first half of 2026.","length":372,"tagName":"p"},{"type":"text","content":"A second protocol defined interim analysis is planned when approximately 50% (or 55) HBeAg+ participants complete 24 weeks of the treatment period. This enr...